Richard P. Junghans - Concepedia

Author

Richard P. Junghans

Also Known As

R JUNGHANS, R Junghans, R P Junghans, R. Junghans, R. P Junghans, R. P. JUNGHANS, R. P. Junghans, R.P Junghans, R.P. Junghans, RICHARD JUNGHANS

181

Publications

7.2K

Citations

H-Index

114

Concepts

All Affiliations

Roger Williams Medical Center Beth Israel Deaconess Medical Center Providence College Boston University Harvard University

About

Richard P. Junghans is an author at Roger Williams Medical Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	45	3.7K
2	Natural Sciences	5	5	248
3	Allergy	5	5	914
4	Engineering	3	3	276
5	Health Sciences	1	1	72

Richard P. Junghans

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Richard P. Junghans, Clark L. Anderson Proceedings of the National Academy of Sciences	1996	675
A humanized antibody that binds to the interleukin 2 receptor. Cary Queen, William P. Schneider, Harold E. Selick, Proceedings of the National Academy of Sciences Immunocytochemical TechniqueAmino AcidsAnti-tac Monoclonal AntibodyImmunologyImmunodominance	1989	627
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin Vijay K. Chaudhary, Gary Queen, Richard P. Junghans, Nature Microbial ToxinToxinologyMedicineVirulence FactorPathogenesis	1989	418
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases Steven C. Katz, Rachel A. Burga, Elise McCormack, Clinical Cancer Research	2015	371
Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response Richard P. Junghans, Qiangzhong Ma, Ritesh Rathore, The Prostate	2016	261
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T Rachel A. Burga, Mitchell Thorn, Gary R. Point, Cancer Immunology Immunotherapy Cancer ImmunosurveillanceHepatocellular CarcinomaLiver PhysiologyImmunologyMyeloid-derived Suppressor Cells	2015	212
Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Robert W. Kozak, Andrew Raubitschek, Saed Mirzadeh, PubMed Vivo SurvivalImmunocytochemical TechniqueImmunologyPharmacotherapyImmunotherapy	1989	171
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery Steven C. Katz, Gary R. Point, Marissa Cunetta, Cancer Gene Therapy Cell TherapyImmunotherapyPeritoneal CarcinomatosisMedicineImmunology	2016	168
Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Richard P. Junghans, T. A. Waldmann, Nicholas F. Landolfi, PubMed ImmunologyImmune RegulationImmunologic MechanismAntigen ProcessingImmunotherapy	1990	151
RNA Leaching of Transcription Factors Disrupts Transcription in Myotonic Dystrophy Alex Ebralidze, Yin Wang, Victoria Petkova, Science EngineeringGeneticsMolecular BiologyMutant RnaRna Leaching	2003	149

Page 1